Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis.
Meta-analysis
Schizophrenia
Systematic review
Varenicline
cognition
Journal
Psychopharmacology
ISSN: 1432-2072
Titre abrégé: Psychopharmacology (Berl)
Pays: Germany
ID NLM: 7608025
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
13
08
2019
accepted:
08
11
2019
pubmed:
4
12
2019
medline:
5
6
2020
entrez:
4
12
2019
Statut:
ppublish
Résumé
People with schizophrenia frequently have cognitive dysfunction, which does not respond to pharmacological interventions. Varenicline has been identified as a potential treatment option for nicotinic receptor dysfunction with a potential to treat cognitive impairment in schizophrenia. We conducted a systematic review of Pubmed, Embase, Psycinfo, CINAHL and the Cochrane Schizophrenia Trial Registry for randomised controlled trials of varenicline in people with schizophrenia for cognitive dysfunction. We excluded trials among people with dementia. We then undertook a meta-analysis with the primary outcome of difference in change of cognitive measures between varenicline and placebo as well as secondary outcomes of difference in rates of adverse events. We conducted a sensitivity analysis on smoking status and study duration. We included four papers in the meta-analysis (n = 339). Varenicline was not superior to placebo for overall cognition (SMD = -0.022, 95% CI -0.154-0.110; Z = -0.333; p = 0.739), attention (SMD = -0.047, 95% CI -0.199-0.104; Z = -0.613; p = 0.540), executive function (SMD = -0.060, 95% CI -0.469-0.348; Z =- 0.290; p = 0.772) or processing speed (SMD = 0.038, 95% CI -0.232-0.308; Z = 0.279; p = 0.780). There was no difference in psychotic symptoms, but varenicline was associated with higher rates of nausea. Sensitivity analyses for smoking status and study duration did not alter the results. Within the present literature, varenicline does not appear to be a useful target compound for improving cognitive impairment in schizophrenia. Based on these results, a trial would need over 2500 participants to be powered to show statistically significant findings.
Sections du résumé
BACKGROUND
BACKGROUND
People with schizophrenia frequently have cognitive dysfunction, which does not respond to pharmacological interventions. Varenicline has been identified as a potential treatment option for nicotinic receptor dysfunction with a potential to treat cognitive impairment in schizophrenia.
METHODS
METHODS
We conducted a systematic review of Pubmed, Embase, Psycinfo, CINAHL and the Cochrane Schizophrenia Trial Registry for randomised controlled trials of varenicline in people with schizophrenia for cognitive dysfunction. We excluded trials among people with dementia. We then undertook a meta-analysis with the primary outcome of difference in change of cognitive measures between varenicline and placebo as well as secondary outcomes of difference in rates of adverse events. We conducted a sensitivity analysis on smoking status and study duration.
RESULTS
RESULTS
We included four papers in the meta-analysis (n = 339). Varenicline was not superior to placebo for overall cognition (SMD = -0.022, 95% CI -0.154-0.110; Z = -0.333; p = 0.739), attention (SMD = -0.047, 95% CI -0.199-0.104; Z = -0.613; p = 0.540), executive function (SMD = -0.060, 95% CI -0.469-0.348; Z =- 0.290; p = 0.772) or processing speed (SMD = 0.038, 95% CI -0.232-0.308; Z = 0.279; p = 0.780). There was no difference in psychotic symptoms, but varenicline was associated with higher rates of nausea. Sensitivity analyses for smoking status and study duration did not alter the results.
CONCLUSION
CONCLUSIONS
Within the present literature, varenicline does not appear to be a useful target compound for improving cognitive impairment in schizophrenia. Based on these results, a trial would need over 2500 participants to be powered to show statistically significant findings.
Identifiants
pubmed: 31792645
doi: 10.1007/s00213-019-05396-9
pii: 10.1007/s00213-019-05396-9
doi:
Substances chimiques
Nicotinic Agonists
0
Varenicline
W6HS99O8ZO
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-19Références
J Clin Pharmacol. 2006 Dec;46(12):1439-48
pubmed: 17101743
J Psychiatr Res. 2015 Jan;60:14-21
pubmed: 25306261
Arch Gen Psychiatry. 2011 Dec;68(12):1195-206
pubmed: 21810630
Int J Neuropsychopharmacol. 2018 May 14;:null
pubmed: 29762677
Br J Psychiatry. 1997 Oct;171:360-3
pubmed: 9373426
Pharmacol Biochem Behav. 2011 Aug;99(2):245-53
pubmed: 21115035
Schizophr Res. 2013 Jul;147(2-3):241-52
pubmed: 23619055
Biol Psychiatry. 2011 Jan 1;69(1):12-8
pubmed: 20965497
Eur Arch Psychiatry Clin Neurosci. 2015 Apr;265(3):259-68
pubmed: 25283510
Syst Rev. 2012 Feb 09;1:2
pubmed: 22587842
Aust N Z J Psychiatry. 2008 Jun;42(6):496-504
pubmed: 18465376
Schizophr Res Cogn. 2015 Jan 28;2(1):26-32
pubmed: 29379758
J Int Neuropsychol Soc. 2019 Aug;25(7):750-760
pubmed: 31104647
Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:45-53
pubmed: 28065843
Crit Rev Neurobiol. 2000;14(1):1-21
pubmed: 11253953
Neuropsychopharmacology. 2012 Feb;37(3):660-8
pubmed: 22048460
Schizophr Res. 2019 May;207:1-2
pubmed: 30930035
Schizophr Res. 2000 Sep 29;45(1-2):169-73
pubmed: 10978884
Arch Gen Psychiatry. 1994 Feb;51(2):124-31
pubmed: 7905258
Schizophr Res. 1995 Sep;17(1):25-33
pubmed: 8541247
Psychopharmacol Bull. 1992;28(3):297-302
pubmed: 1480733
Br Med Bull. 1997 Jan;53(1):135-55
pubmed: 9158290
Biol Psychiatry. 2017 Jan 1;81(1):9-20
pubmed: 27720198
Biol Psychiatry. 2001 Dec 1;50(11):884-97
pubmed: 11743943
Psychopharmacology (Berl). 2014 Feb;231(4):765-75
pubmed: 24114425
Br J Psychiatry. 2010 Sep;197(3):174-9
pubmed: 20807960
Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12078-83
pubmed: 23818597
Psychol Med. 2017 Jul;47(10):1848-1864
pubmed: 28241891
Memory. 2010 May;18(4):394-412
pubmed: 20408039
Biol Psychiatry. 2004 Oct 15;56(8):540-3
pubmed: 15476682
PLoS One. 2016 Jan 05;11(1):e0143490
pubmed: 26730716